Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REP. WAXMAN WILL REVISIT ORPHAN DRUG EXCLUSIVITY NEXT YEAR

Executive Summary

REP. WAXMAN WILL REVISIT ORPHAN DRUG EXCLUSIVITY NEXT YEAR, House Commerce/Health Subcommittee Counsel William Corr predicted at a March 28 meeting of the Food and Drug Law Institute. "I think it will be in the next session of Congress," Corr said. "We will be back with additional proposals. I don't know if it will be the same one. But we have to come back because it . . . is a matter of time." Corr said that as more profitable orphan drugs are approved, "our view is that the support for the Act will diminish, certainly the support for exclusivity will diminish." He continued: "I argue that it will lose its support if we have a series of drugs that are approved, that are there clearly because they're trying to block competition. It's a drug that they have every financial incentive in the world to make. The Act is simply being used to block others, which is not the way it is intended." Corr cited pentamidine, Burroughs Wellcome's Retrovir (AZT), and human growth hormone as examples of profitable orphan drug products, and predicted that erythropoietin (EPO) will be "the next one." Amgen expects approval for EPO for end-stage renal disease by the end of the year. Waxman (D-Calif.) decided last month that he would bring legislation to reauthorize orphan product research to the House floor, without including amendments to the Act's exclusivity provisions. His bill passed the House, on March 22 by a 409 to 1 vote. The legislation is expected to be considered by the Senate any day. Corr explained Waxman's reasons for dropping endorsement of the amendments to the exclusivity provisions of the Act. "Eventually we decided to go forward with the legislation without any change in the exclusivity rules," he said. "We did that because of our concern that the Orphan Drug Act grant program has to be reauthorized. You can not imagine the difficulties on the Hill with the budget this year." Corr pointed out that the budget "limits the discretionary spending to a 2% increase in FY '89." The Orphan Drug Act, as it is currently written, provides "a safe haven" for the biotech companies when they are uncertain about the status of their patents, Corr said. "If you have any question about your patent status and you can be the first one approved, you've got seven years . . . Why not take advantage of it?" Corr added that the House judiciary committee had been asked to rectify the problem, so that companies would not try to get every drug approved as an orphan. However the committee said it had not yet discussed the issue with the biotech industry. As a result, Corr noted, "there is not going to be a solution, at least in the near future, to the patent laws."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel